Sabon Bincike don Marasa Lafiyar Cutar Cancer

Caris Life Sciences® ita ce gabatar da binciken da ke ba da zurfin fahimtar cewa ƙwayar ƙwayar ƙwayar cuta ta kwayoyin halitta da ke da alaƙa da girman bayyanar miyagun ƙwayoyi, wanda aka tsara ta hanyar p53, yana da alaƙa da sakamakon asibiti akan ka'idodin chemotherapeutic na yau da kullun da ake amfani da su don magance ciwon daji na launi na metastatic (CRC). Za a gabatar da waɗannan sakamakon a taron 2022 American Association for Cancer Research (AACR) Taron Shekara-shekara da ake gudanarwa Afrilu 8 - 13, 2022 a New Orleans, Louisiana.

Binciken tare da takarda mai taken, "Sa hannu kan sa hannu kan kwayar cutar kwayar cutar da ke haifar da kwayar cutar ga marasa lafiya marasa lafiya da keɓaɓɓu bisa ga matsayin p53 da jiyya tare da FOLFOX, 5-FU, oxaliplatin ko irinotecan” (Abstract #1231), Wafik El-Deiry ya jagoranta. , MD, Ph.D., FACP, Daraktan Cibiyar Cancer ta Legorreta ta Jami'ar Brown, Mataimakin Dean a Makarantar Kiwon Lafiya ta Warren Alpert, memba na Caris' Precision Oncology Alliance (POA). Caris' POA babbar hanyar sadarwa ce ta manyan cibiyoyin ciwon daji a duk faɗin duniya waɗanda ke yin haɗin gwiwa don haɓaka daidaitaccen ilimin oncology da bincike-bincike mai alamar halitta. An gabatar da wannan aikin a New Orleans ta hanyar Lindsey Carlsen, ɗalibin da ya kammala karatun digiri na Pathobiology a cikin EL-DEIRY Lab a Brown.

Makasudin wannan binciken shine don gano alamomin tsinkaya don maganin chemotherapies da aka yi amfani da su a cikin CRC. Binciken ya yi amfani da layin salula na CRC don gano nau'o'in jinsin da aka bayyana daban-daban biyo bayan 5-fluorouracil, irinotecan, ko oxaliplatin magani kuma ya ƙulla sa hannu bisa ga matsayin p53. Daga waɗannan nazarin in vitro, masu bincike sun bincika ko waɗannan kwayoyin halitta da sa hannu na gene zasu iya yin la'akari da sakamakon marasa lafiya na CRC bayan chemotherapy (FOLFOX, 5-fluorouracil, irinotecan ko oxaliplatin). 2,983 nau'in daji da 6,229 asarar-na aiki p53 samfuran haƙuri na CRC an bincika su ta hanyar DNA/RNA na gaba-gaba a Kimiyyar Rayuwa ta Caris. Sakamakon rayuwa na ainihi an samo asali ne daga bayanan da'awar inshora da kimanta Kaplan-Meier. Dukansu maganganu masu tsinkaya da marasa kima suna da tasiri mai mahimmanci akan sakamakon rayuwa bayan takamaiman jiyya na miyagun ƙwayoyi.

"Wannan binciken yana taimaka mana mu fahimci mahimmancin da sa hannun jinsin halittu ke da shi wajen nuna ingantaccen iya hasashen idan aka kwatanta da kwafin mutum ɗaya," in ji El-Deiry. "Haɓaka bincike na asali da na asibiti, wannan binciken yana ba mu damar fahimtar waɗanne hanyoyin kwantar da hankali ne za su iya amfanar marasa lafiya na CRC." Binciken ya gano cewa bayyanar cututtuka na kwayoyin halitta da ke da alaka da maganin miyagun ƙwayoyi na iya yin hasashen sakamakon bayan maganin chemotherapy:

• Babban EGR1 da FOS mRNA da kansa suna tsinkayar amsa ga FOLFOX a cikin marasa lafiya da ciwon daji na p53.

• Ƙananan CCNB1 mRNA yana daidaitawa tare da kyakkyawan hangen nesa na marasa lafiya na CRC tare da ciwace-ciwacen da ke dauke da asarar TP53 na maye gurbi.

• Ƙananan magana na BTG2 yana annabta mafi kyawun tsinkaye a cikin marasa lafiya tare da MSI-High TP53 mutated ciwace-ciwacen daji.

• Sa hannu kan kwayoyin halitta na iya nuna ingantacciyar ikon tsinkaya idan aka kwatanta da tasirin kwafin mutum ɗaya.

"Caris ya mayar da hankali ga masu nazarin halittu wanda zai iya yin la'akari da amsawar haƙuri ga sababbin hanyoyin kwantar da hankali, amma kuma ya gwada da kuma maganin chemotherapies na gaskiya kamar FOLFOX," in ji W. Michael Korn, MD, Babban Jami'in Harkokin Kiwon Lafiya a Caris. "Muna farin cikin ganin damar binciken fassarar fassarar da aka ba da ƙarfi ta hanyar manyan bayanai masu yawa da kayan aikin nazari waɗanda Caris ya haɓaka kuma ya ci gaba da samun ci gaba."

Cikakkun bayanan kwayoyin Caris yana tantance gabaɗayan exome (DNA), gabaɗayan transcriptome (RNA) da furcin furotin, yana ba da albarkatu mara misaltuwa da kyakkyawar hanyar gaba don gudanar da binciken fassarar don haɓaka gano ganowa, ganowa, saka idanu, zaɓin magani da haɓaka magunguna. don inganta yanayin ɗan adam.

Caris zai gabatar da ƙarin bayanai daga binciken da ke nuna mahimmancin rawar da madaidaicin magani da kuma bayanan kwayoyin halitta a cikin maganin ciwon daji. Za a gabatar da duk gabatarwa ta kan layi ta gidan yanar gizon Caris daga Afrilu 8, 2022.

Ƙarin Gabatarwa Yana Nuna Tasirin Cikakkun Bayanan Halitta da Ƙwararren Ƙwararren Ƙwararru

• Ƙimar haɓakar gyare-gyare na FGF / FGFR a cikin ciwon nono masu cin zarafi (Abstract #5793)FGFR siginar siginar ita ce tsakiya don yaduwar kwayar cutar kansa, ƙaura, angiogenesis da rayuwa; Canje-canjen FGFR sun zama masu aiki a asibiti a cikin karuwar nau'ikan ciwon daji. Wannan binciken ya kimanta abubuwan da suka faru da halayen sauye-sauyen FGF/FGFR da yawa a cikin sama da 12,000 masu kamuwa da cutar kansar nono kuma ya ba da haske game da manyan canje-canjen FGF/FGFR a cikin nau'ikan tarihin tarihi da kwayoyin halitta da kuma wuraren metastatic na kansar nono daban-daban. Bugu da ari, ƙungiyoyin gyare-gyare na FGFR da juriya ga hanyoyin kwantar da hankali an nuna su a cikin babban bayanan asibiti tare da sakamakon kwayoyin da suka dace.

• Halin kwayoyin halitta da na rigakafi na nau'ikan nau'ikan EGFR a cikin ciwon huhu marasa ƙananan ƙwayoyin cuta (NSCLC) (Abstract #4119) Yayin da EGFR mutant NSCLC ciwace-ciwacen daji gabaɗaya suna da tsayayya ga masu hana PD-1/PD-L1, ƙananan ƙananan marasa lafiya na iya samun amsa mai dorewa. . EGFR-mutant ciwace-ciwacen daji suna nuna mahimmancin nau'in kwayoyin halitta, duk da haka, akwai rashin haske akan bayanan kwayoyin halitta da na rigakafi na EGFR maye gurbi, kuma ƙarin bayanin wannan na iya taimakawa wajen gano marasa lafiya da zasu iya amsawa ga hanyoyin kwantar da hankali. Yin amfani da bayanan kwayoyin halitta da yawa da aka samar ta hanyar Tsarin Halitta na gaba na DNA da RNA akan babban rukunin ciwace-ciwacen NSCLC, wannan binciken ya tabbatar da raguwar rigakafi da ke da alaƙa da mafi yawan nau'ikan maye gurbi na EGFR da aka bayyana ta hanyar biomarkers ciki har da PD-L1, TMB da CD8+ T. shigar da kwayar halitta; kuma yana bayyana ƙarancin maye gurbi na EGFR mai alaƙa da ingantaccen bayanin martaba na rigakafi wanda zai iya ba da shawarar karɓar maganin rigakafi.